Phase
Startup
Apriligen
Apriligen Sweden AB develops curative gene therapies for children with Diamond‑Blackfan Anemia (DBA), a rare, life‑shortening blood disorder with limited treatment options. The company is based on pioneering research at Lund University and is part of the Apriligen group, for which all research and development activities are conducted at Apriligen Sweden AB. The Apriligen group runs the world’s only gene therapy program for DBA, with approval to initiate clinical trials and Fast Track designation from the U.S. FDA. Apriligen Sweden AB is based in Lund.
New technologies for next-gen antibody therapeutics
Single Molecule Nanowire Biosensors for Diagnostics
Medicines for acute systemic inflammatory diseases
Develops gene therapies for children with DBA - Diamond‑Blackfan Anemia
Cancer immunotherapies based in cell reprogramming
Develops antibody therapies targeting invasive Group A Streptococcus.
Early cancer detection through chemical signature preserved in hair
Introducing the fungal based industrial revolution
Automated microscopy image acquisition and analysis
Rapid analyses of human genetic variants
Nanosystems for oral biologics delivery
Fighting iron deficiency
Implants of magnesium alloys
Developing future targeted immunotherapies in cancer
Ultrasound analysis for stroke risk assessment
Medical device that reduces pain during vein operation
Pioneering neurometabolic medicine for neurodegenerative diseases
Builds gene therapy viral vectors
Early detection of pancreatic cancer
Develops methods for producing high-quality phospholipids.
Bio-based vegan coating for fruits and vegetables
Medtech solution for preventing pressure ulcers
Next-generation precision medicine
Converting waste flows into valuable raw materials
Innovative systemic anti-inflammatory treatments
Safer medical needles for prostate biopsy
